FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

For more information about Candel, visit: www.candeltx.com.

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

The results from Part 1 are consistent with prior clinical studies of this first-in-class lutetium radio antibody-drug conjugate (rADC) therapy.

This article was reviewed by Darragh O’Carroll, MD. Key takeaways: Testosterone cream is a needle-free testosterone therapy ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...

The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...

Lantheus said that the FDA approved its PYLARIFY TruVu injection.

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for la ...

Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced that it has received notification from its licensing ...

Penis Botox isn't all that uncommon these days and is chosen for a range of reasons. Tech entrepreneur Bryan Johnson revealed ...

MILAN — A plastic surgeon renowned for penis-enlarging procedures, including the injection of hyaluronic acid, says he provided the service last month to a ski jumper. The assertion comes with the ski ...